Startup profile · funding coverage

IMU Biosciences

UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.

Stage

series a

Status

private

Coverage

full

Why IMU Biosciences is interesting

The immune system underlies most disease, yet remains poorly mapped. IMU builds large-scale immune-profiling to turn immune data into actionable diagnostics and therapeutic targets. - Immune dysregulation drives cancer, autoimmunity, and chronic disease. - High-throughput profiling plus AI can finally decode immune complexity. - Pharma needs better targets and patient stratification. UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.

Key facts

Disclosed financing: $53M (Series A)
Covered in 1 Venture Capital Tracker article(s)

Industries

AI & Machine Learning Biotech & Life Sciences

Industry hub pages are rolling out from our fund-derived baseline taxonomy.